{"id":19703,"date":"2023-04-12T20:37:00","date_gmt":"2023-04-12T12:37:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19703"},"modified":"2024-12-24T20:43:57","modified_gmt":"2024-12-24T12:43:57","slug":"priority-review-status-anticipated-for-hh-003-bi655130-vis649-and-remternetug-by-cde","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19703","title":{"rendered":"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE"},"content":{"rendered":"\n

The Center for Drug Evaluation (CDE) website has indicated that Huahui Health\u2019s HH-003, Boehringer Ingelheim\u2019s BI655130, Otsuka Pharma\u2019s VIS649, and Eli Lilly\u2019s Remternetug are on track to obtain priority review statues. These drugs target chronic hepatitis D virus (HDV), prevention of generalized pustular psoriasis (GPP), IgA nephropathy, and early Alzheimer’s disease (AD), respectively.<\/p>\n\n\n\n

HH-003: A Potential Cure for Chronic Hepatitis B and HDV<\/strong>
HH-003, an in-house developed monoclonal antibody (mAb) by Huahui Health, is expected to functionally cure chronic hepatitis B virus (HBV) and HDV. It has shown an effective antiviral response in patients undergoing immune clearance in a Phase Ib study involving chronic HBV patients.<\/p>\n\n\n\n

BI655130: A New Hope for GPP Patients<\/strong>
BI655130 (spesolimab), a first-in-class mAb targeting IL-36R developed by Boehringer Ingelheim, has demonstrated significant improvement in skin symptoms for patients with GPP in previous studies. GPP is a rare and severe disease characterized by extensive rupture of blisters on the skin, which can lead to organ failure and even death.<\/p>\n\n\n\n

VIS649: An APROIL mAb for IgA Nephropathy<\/strong>
VIS649 (sibeprenlimab), an A proliferation-inducing ligand (APRIL) mAb originated by Visterra, was acquired by Otsuka via a USD 430 million deal in 2018. This acquisition included VIS649 alongside other kidney disease drug candidates, positioning it as a potential treatment for IgA nephropathy.<\/p>\n\n\n\n

Remternetug: Targeting Early Alzheimer’s Disease<\/strong>
Remternetug (LY3372993), an N3pG-A \u03b2 Amyloid protein antibody developed by Eli Lilly, has shown the ability to clear amyloid protein and deep plaques with good safety in early studies. Eli Lilly initiated the Phase III TRAILRUNNER-ALZ1 study in August 2022 to assess the efficacy and safety of the drug in early AD patients, with the primary endpoint being the percentage of patients with amyloid plaques cleared at the end of treatment. The study, conducted in the US and Japan, is expected to conclude in 2025.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The Center for Drug Evaluation (CDE) website has indicated that Huahui Health\u2019s HH-003, Boehringer Ingelheim\u2019s…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,390,34,199,2198,439,24,89],"class_list":["post-19703","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-boehringer-ingelheim","tag-breakthrough-therapy","tag-eli-lilly","tag-huahui-health","tag-otsuka-pharmaceutical","tag-rare-orphan-disease-drugs","tag-viral-hepatitis"],"yoast_head":"\nPriority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) website has indicated that Huahui Health\u2019s HH-003, Boehringer Ingelheim\u2019s BI655130, Otsuka Pharma\u2019s VIS649, and Eli Lilly\u2019s Remternetug are on track to obtain priority review statues. These drugs target chronic hepatitis D virus (HDV), prevention of generalized pustular psoriasis (GPP), IgA nephropathy, and early Alzheimer's disease (AD), respectively.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19703\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19703\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-12T12:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T12:43:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19703#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19703\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE\",\"datePublished\":\"2023-04-12T12:37:00+00:00\",\"dateModified\":\"2024-12-24T12:43:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19703\"},\"wordCount\":321,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Boehringer Ingelheim\",\"Breakthrough therapy\",\"Eli Lilly\",\"Huahui Health\",\"Otsuka Pharmaceutical\",\"Rare \\\/ orphan disease drugs\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19703#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19703\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19703\",\"name\":\"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-12T12:37:00+00:00\",\"dateModified\":\"2024-12-24T12:43:57+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) website has indicated that Huahui Health\u2019s HH-003, Boehringer Ingelheim\u2019s BI655130, Otsuka Pharma\u2019s VIS649, and Eli Lilly\u2019s Remternetug are on track to obtain priority review statues. These drugs target chronic hepatitis D virus (HDV), prevention of generalized pustular psoriasis (GPP), IgA nephropathy, and early Alzheimer's disease (AD), respectively.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19703#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19703\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19703#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE - Insight, China's Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) website has indicated that Huahui Health\u2019s HH-003, Boehringer Ingelheim\u2019s BI655130, Otsuka Pharma\u2019s VIS649, and Eli Lilly\u2019s Remternetug are on track to obtain priority review statues. These drugs target chronic hepatitis D virus (HDV), prevention of generalized pustular psoriasis (GPP), IgA nephropathy, and early Alzheimer's disease (AD), respectively.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19703","og_locale":"en_US","og_type":"article","og_title":"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19703","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-12T12:37:00+00:00","article_modified_time":"2024-12-24T12:43:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19703#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19703"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE","datePublished":"2023-04-12T12:37:00+00:00","dateModified":"2024-12-24T12:43:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19703"},"wordCount":321,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Boehringer Ingelheim","Breakthrough therapy","Eli Lilly","Huahui Health","Otsuka Pharmaceutical","Rare \/ orphan disease drugs","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19703#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19703","url":"https:\/\/flcube.com\/?p=19703","name":"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-12T12:37:00+00:00","dateModified":"2024-12-24T12:43:57+00:00","description":"The Center for Drug Evaluation (CDE) website has indicated that Huahui Health\u2019s HH-003, Boehringer Ingelheim\u2019s BI655130, Otsuka Pharma\u2019s VIS649, and Eli Lilly\u2019s Remternetug are on track to obtain priority review statues. These drugs target chronic hepatitis D virus (HDV), prevention of generalized pustular psoriasis (GPP), IgA nephropathy, and early Alzheimer's disease (AD), respectively.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19703#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19703"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19703#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19703"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19703\/revisions"}],"predecessor-version":[{"id":19706,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19703\/revisions\/19706"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}